newsfilter
← Latest News
GlobeNewswire·

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

  • Psyence Biomedical Ltd. (NASDAQ: PBM) announced voting results from its Annual & Special Meeting held on February 12, 2026.
  • Shareholders approved all matters presented, including the election of all director nominees, the appointment of MNP LLP as auditors, & authorization for the Board to implement share consolidation.
  • The Board was authorized to consolidate common shares at a ratio of up to 250:1, with the specific ratio & timing to be determined by the Board.
  • No share consolidation will occur unless the Board decides to implement it, subject to regulatory & exchange approvals.
  • Psyence BioMed is a Nasdaq-listed biopharmaceutical company developing nature-derived psilocybin & ibogaine therapies for mental health needs.
  • Forward-looking statements include risks regarding Nasdaq listing compliance, share price volatility, regulatory changes, & clinical trial outcomes.
  • The Company has not conducted clinical trials for its proposed products & makes no medical claims regarding efficacy or safety.